We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Genentech, a member of the Roche Group, announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma ...